Abstract：Therapeutic drug monitoring (TDM) studies the process of drugs in vivo based on pharmacokinetics (PK). It is an important means of clinical individualized drug use to achieve optimal pharmacodynamics (PD). Due to the special pathophysiological state of patients with critical illness, there are obvious differences in drug concentration between themselves and individuals during treatment, which increases the risk of insufficient treatment dose or drug toxicity. Carbapenem antimicrobial agents are widely used in anti infection treatment of patients with critical illness. Combined with PK / PD parameters, it is necessary to use TDM to guide clinical treatment, but the clinical implementation is still not standardized at present, and the effectiveness is controversial. This paper reviews the application progress of carbapenem antimicrobial agents TDM in patients with critical illness.
白静 刘景峰 段美丽. 碳青霉烯类治疗药物浓度监测在危重症患者中的应用进展[J]. 中国医药导报, 2022, 19(13): 55-58.
BAI Jing LIU Jingfeng DUAN Meili. Progress of the application of therapeutic drug monitoring of carbapenem in patients with critical illness#br#. 中国医药导报, 2022, 19(13): 55-58.
[1] Rhodes A，Evans LE，Alhazzani W，et al. Surviving sepsis campaign：international guidelines for management of severe sepsis and septic shock：2016 [J]. Intensive Care Med，2017，43（3）：304-377.
[2] Marshall JC. Inflammation，coagulopathy，and the pathogenesis of multiple organ dysfunction syndrome [J]. Crit Care Med，2001，29（7 Suppl）：S99-S106.
[3] Uchino S，Kellum JA，Bellomo R，et al. Acute renal failure in critically ill patients：a multinational，multicenter study [J]. JAMA，2005，294（7）：813-818.
[4] Vincent JL，Rello J，Marshall J，et al. International study of the prevalence and outcomes of infection in intensive care units [J]. JAMA，2009，302（21）：2323-2329.
[5] Rodloff AC，Goldstein EJC，Torres A. Two decades of imipenem therapy [J]. J Antimicrob Chemother，2006，58（5）：916-929.
[6] McAleenan A，Ambrose PG，Bhavnani SM，et al. Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals：A systematic review [J]. J Antimicrob Chemother 2020，75（6）：1374-1389.
[7] Abdul-Aziz MH，Alffenaar JC，Bassetti M，et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients：A position paper [J]. Intensive Care Med，2020， 46（6）：1127-1153.
[8] Kang JS，Lee MH. Over view of Therapeutic Drug Monitoring [J]. Korean J Intern Med，2009，24（1）：1-10.
[9] Garzón V，Bustos RH，Pinacho DG. Personalized Medicine for Antibiotics：The Role of Nanobiosensors in Therapeutic Drug Monitoring [J]. J Pers Med，2020，10（4）：147.
[10] Ates HC，Roberts JA，Lipman J，et al. On-Site Therapeutic Drug Monitoring [J]. Trends Biotechnol，2020，38（11）：1262-1277.
[11] Clarke W. In Clinical Challenges in Therapeutic Drug Monitoring [M]. San Diego：Elsevier，2016：1-15.
[12] Junaid T，Wu X，Thanukrishnan H，et al. In Clinical Pharmacy Education，Practice and Research [M]. Amsterdam：Elsevier，2019：425-436.
[13] Neugebauer S，Wichmann C，Bremer-Streck S，et al. Simultaneous Quantification of Nine Antimicrobials by LC-MS/MS for Therapeutic Drug Monitoring in Critically Ill Patients [J]. Ther Drug Monit，2019，41（1）：29-37.
[14] Muller AE，Huttner B，Huttner A. Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit：Which Agents，Which Patients and Which Infections？[J]. Drugs，2018，78（4）：439-451.
[15] Luhr R，Cao Y，S?觟derquist B，et al. Trends in sepsis mortality over time in randomised sepsis trials：A systematic literature review and meta-analysis of mortality in the control arm，2002—2016 [J]. Crit Care 2019，23（1）：241.
[16] 温爱萍，李哲，李任，等.HPLC法测定人血浆中游离亚胺培南浓度[J].中国药物应用与监测，2015（3）：151-154.
[17] Bloos F，Ruddel H，Thomas-Ruddel D，et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality：a cluster randomized trial [J]. Intensive Care Med，2017，43（11）：1602-1612.
[18] Veiga RP，Paiva JA. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients [J]. Critical Care，2018， 22（1）：233.
[19] Zhanel GG，Wiebe R，Dilay L，et al. Comparative Review of the Carbapenems [J]. Drugs，2007，67（7）：1027-1052.
[20] Mouton JW，Touzw DJ，Horrevorts AM，et al. Comparative pharmacokinetics of the carbapenems：Clinical implications [J]. Clin Pharmacokinet，2000，39（3）：185-201.
[21] Guidelines for Intensive Care Unit Admission，Discharge，and Triage. Task Force of the American College of Critical Care Medicine，Society of Critical Care Medicine [J]. Crit Care Med，1999，27（3）：633-638.
[22] Gon?觭alves-Pereira J，Póvoa P. Antibiotics in critically ill patients：a systematic review of the pharmacokinetics of b-lactams [J]. Crit Care，2011，15（5）：R206.
[23] Sinnollareddy MJ，Roberts MS，Lipman J，et al. Beta-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization：A structured review [J]. Clin Exp Pharmacol Physiol，2012， 39（6）：489-496.
[24] Roberts JA，Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient [J]. Crit Care Med，2009， 37（3）：840-851.
[25] Gon?觭alves-Pereira J，Silva NE，Mateus A，et al. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients [J]. BMC Pharmacol Toxicol，2014，15（1）：21.
[26] Onufrak NJ，Forrest A，Gonzalez D. Pharmacokinetic and pharmacodynamic principles of anti-infective dosing [J]. Clin Ther，2016，38（9）：1930-1947.
[27] Coufignall C，Pajot O，Laouénan C，et al. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens [J]. Br J Clin Pharmacol，2014， 78（5）：1022-1034.
[28] Burkhardt O. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia：pharmacokinetics with special consideration of free-drug concentration [J]. J Antimicrob Chemother. 2007，59（2）：277-284.
[29] Ehmann L，Zoller M，Minichmayr IK，et al. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients：A prospective observational study [J]. Crit Care，2017，21（1）：263.
[30] Romain G，Sihem B，Youssef B，et al. Optimization of the treatment with betalactam antibiotics in critically ill patients——guidelines from the French Society of Pharmacology and Therapeutics（SociétéFran?觭aise de Pharmacologie et Thérapeutique——SFPT）and the French Society of Anaesthesia and Intensive Care Medicine（SociétéFran?觭aise d’Anesthésieet Réanimation——SFAR）[J]. Crit Care，2019，23（1）：104.
[31] Roberts JA，Paul SK，Akova M，et al. DALI：defining antibiotic levels in intensive care unit patients：are current β-lactam antibiotic doses sufficient for critically ill patients？[J]. Clin Infect Dis，2014，58（8）：1072-1083.
[32] Eucast T，Mic H，Mic E，et al. European Committee on Antimicrobial Susceptibility Testing：Breakpoint Tables for Interpretation of MICs and Zone Diameters [EB/OL]. Version 10.0. http：//www.eucast.org.
[33] De Waele JJ，Carrette S，Carlier M，et al. Therapeutic drug monitoring-based dose optimization of piperacillin and meropenem：A randomized controlled trial [J]. Intensiv Care Med，2013，40（3）：380-387.
[34] Aldaz A，Grijalba AII，Ortega A，et al. Effectiveness of Pharmacokinetic/Pharmacodynamic-Guided Meropenem Treatment in Critically Ⅲ Patients：A Comparative Cohort Study [J]. Ther Drug Monit，2021，43（2）：256-263.
[35] Bricheux A，Lenggenhager L，Hughes S，et al. Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients：A retrospective cohort study [J]. Clin Microbiol Infect 2019，25：383.e1-383.e4.
[36] Sharon LW，Hans LR，Nicolas DP，et al. Carbapenem Therapeutic Drug Monitoring in Critically Ill Adult Patients and Clinical Out comes：A Systematic Review with Meta-Analysis [J]. Antibiotics，2021，10（2）：177.
[37] Abdulla A，Ewoldt TMJ，Hunfeld NGM，et al. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients：The DOLPHIN trial protocol of a multi-centre randomized controlled trial [J]. BMC Infect Dis，2020，20（1）：57.
京公网安备 11010502046598号